Peak Bio, Inc. announced that it entered into a subscription agreement for private placement of 50,000 common shares at an issue price of $10 per share for gross proceeds of $500,000 on December 30, 2022. The company will also issue 46,500 warrants to purchase common shares, at an exercise price of $0.01 per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0086 USD | 0.00% | 0.00% | -95.41% |
03-05 | Akari Therapeutics, Plc entered into a definitive agreement to acquire Peak Bio, Inc.. | CI |
02-16 | Peak Bio, Inc. announced that it has received $2.238 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-95.41% | 195K | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- PKBO Stock
- News Peak Bio, Inc.
- Peak Bio, Inc. announced that it expects to receive $0.5 million in funding